Protective agent, kigelia africana fruit extract, against cisplatininduced kidney oxidant injury in spraguedawley rats

Asian Journal of Pharmaceutical and Clinical Research

Volumn 3, Issue 2, 2010, Pages 84-88

  Azu, Onyemaechi O ^a   Duru, Francis I O ^a   Osinubi, Abraham A ^a   Noronha, Crescie C ^a   Elesha, Stephen O ^a   Okanlawon, Abayomi O ^a  

^a UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

BUN; Catalase; Creatinine; Histology; Kigelia africanacisplatin

Indexed keywords

ANTIOXIDANT; CISPLATIN; CREATININE; KIGELIA AFRICANA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; ENZYME INHIBITION; FRUIT; HISTOPATHOLOGY; KIDNEY TUBULE NECROSIS; KIGELIA AFRICANA; LD 50; LIPID PEROXIDATION; MEDICINAL PLANT; MORTALITY; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 77953368822     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aiyeloja AA, Bello OA. Ethnobotanical potentials of common herbs in Nigeria: A case study of Enugu state. Educational Research and Review 2006; 1:16-22.
2. Blench R. Hausa names for plants and trees. ODI (Overseas Development Institute). 2003; pp 1-66.
3. Roodt V. Kigelia africana in: the shell field guide to the common trees of the okavango delta and moremi game reserve. Gaborone, Botswana: Shell Oil Botswana 1992.
4. Asekun OT, Olusegun E, Adebola O. The volatile constituents of the leaves and flowers of Kigelia africana Benth. Flavour and Fragr J 2007; 22:21-23.
5. Kolodziej H. Protective role of Kigelia africana fruits against benzo(a)pyrene-induced fore-stomach tumourigenesis in mice and against albumen-induced inflammation in rats. Pharm Pharmacol Lett 1997; 7:67 - 70.
6. Olaleye MT, Rocha BT. Acetaminophen-induced liver damage in mice: Effects of some medicinal plants on the oxidative defence system. Exp Toxicol Pathol, 2008 Epub ahead of print.
7. Jung UJ, Lee MK, Park YB, Jeon SM, Choi MS. Antihyperglycemic and antioxidant properties of caffeic acid in db/db mice. Journal of Pharmacology and Experimental Therapeutics Fast Forward JPET 2006; 318:476-483.
8. Gulcin I. Antioxidant activity of caffeic acid (3, 4-dihydroxycinnamic acid). Toxicology 2006; 217:213-220.
9. Olthof MR, Hollman PCH, Katan MB. Chlorogenic acid, caffeic acids are absorbed in humans. Journal of Nutrition 2001; 131:66-71.
10. Grace OM, Light ME, Lindsey KL, Mulholland DA, Van Staden J, Jager AJ. Antibacterial activity and isolation of active compounds from the fruits of the traditional African tree Kigelia africana. South Afr J Bot 2002; 68:220-222.
11. Moiden SV, Houghton PJ, Rock P, Croft SL, Aboagye-Nyame F. Activity of extracts and naphthoquinones from Kigelia pinnata against Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. Planta Med 1999; 65:536-40.
12. Weiss CR, Moideen SV, Croft SL, Houghton PJ. Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparium. J Nat Prod 2000; 63:1306-9.
13. Bharti N, Singh S, Naqvi F, Azam A. Isolation and in vitro antiamoeboic activity of iridoids isolated from Kigelia pinnata. General Papers ARKIVOC 2006 x: 69-76.
14. Akah PA. Antidiarrheal activity of Kigelia africana in experimental animals. Journal of Herbs, Spices & Medicinal Plants 1998; 4:31-38.
15. Owolabi OJ, Omogbai EKI. Analgesic and anti-inflammatory activities of the ethanolic stem bark extract of Kigelia africana (Bignoniaceae). African Journal of Biotechnology 2007; 6:582-585.
16. Houghton PJ, Photiou A, Uddin S, Shah P, Browning M, Jackson SJ, et al. Activity of Kigelia pinnata against melanoma and renal carcinoma cell lines, Planta Med 1994; 60:430-3.
17. Picerno P, Autore G, Marzocco S, Meloni M, Sanogo R, Aquino RP. Antiinflammatory activity of verminoside from Kigelia africana and evaluation of cutaneous irritation in cell cultures and reconstituted human epidermis. J Nat Prod 2005; 68:1610-4.
18. Angeloni C, Leoncini E, Malaguti M, Angelini S, Hrelia P, Hrelia S. Role of quercetin in modulating rat cardiomyocyte gene expression profile. Am J Physiol Heart Circ Physiol Jan 4 2008 Epub ahead of print.
19. Santos MR, Rodriguez-Gomez MJ, Justino GC, Charro N, Florencio MH, Mira L. Influence of the metabolic profile on the in vivo antioxidant activity of quercetin under a low dosage oral regimen in rats. Br J Pharmacol Mar 3 2008 Epub ahead of print.
20. Rausch WD, Liu S, Gille G, Radad K. Neuroprotective effects of ginsenosides. Acta Neurobiol Exp (Wars) 2006; 66:369-75.
21. Aminsharifi AR, Talaei T, Kumar V, Sabayan B, Samani S, Mohamadhoseini E. A postulated role of testosterone for prevention of cisplatin gonadal toxicity. Epub. 2007; 525-7.
22. Cepada V, Fuertis MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin toxicity. Anticancer Agents in Medicinal Chemistry 2007; 7:3-18.
23. Amin A, Hamza AA, Kambal A, Daoud S. Herbal extracts counteract cisplatin-mediated cell death in rat testis. Asian J Androl 2008; 10:291-7.
24. International Agency for Research on Cancer (IARC) Cisplatin, In: some antineoplastic and immunosuppressive agents. Lyon, France. IARC monographs on the evaluation of immunosuppressive agents 1981; 26:151-164.
25. International Programme on Chemical Safety (IPCS) Platinum; Environmental health criteria 125. World Health Organisation, Geneva 1991.
26. Skalova S. The diagnostic role of urinary N-acetyl-b-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica 2005; 48:75-80.
27. Raab RP. Diagnostic value of urinary enzyme determinations. Clin Chim Acta 1972; 18:15-22.
28. Khynriam D, Prasad SB. Changes in endogenous tissue glutathione level I relation to murine ascites tumour growth and the anticancer activity of cisplatin. Braz J Med Res 2003; 36:53-63.
29. Lirdi LC, Stupp T, Sasso-Cerri E, Miraglia SM. Amifostine protective effect on cisplatin-treated rat testis. The Anatomical Record 2008; 291:797-808.
30. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci 2007; 334:115-124.
31. Badary OA, Abdel-Maksoud S, Ahmed WA,Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sciences 2005; 76:2125-2135.
32. Razo-Rodriguez AC, Chirino YI, Sanchez-Gonzalez DJ, Martinez- Martinez CM, Cruz C, Pedraza-Chaverri J. Garlic powder ameliorates cisplatin-induced nephrotoxicty and oxidative stress. Journal of Medicinal Food 2008; 11:582-586.
33. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies 2004; 3:294-300.
34. Heidman HT, Gerkens JF, Jackson EK, Branch RA. Attenuation of cisplatin induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Arch Pharmacol 1985; 329:201-5.
35. Montine TJ, Borch RF. Role of endogenous sulfur containing nucleophiles in an in vitro model of cis-diammine-dichloroplatiniuminduced nephrotoxicity. Biochem Pharmacol 1990; 39:1751-7.
36. Jones TW, Chopra S, Kaufman JS, Flamenbaum W, Trump B. Cisdiammine-dichloroplatinium-induced acute renal failure in the rat. Lab Invest 1985; 52:363-74.
37. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxocity and protection by Milk Thistle extract in rats. eCAM 2005; 26:1-4.
38. Rubanyi GM, Vanhoutte PM. Superoxide anions and hypoxia inactivate endothelium derived relaxing factor. Am J Physiol 1986; 250:H822-7.
39. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24:354-65.
40. Goren MP, Wright RK, Horowit ME. Cumulative renal damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1986; 18:69-73.